Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director comp.
Appointed director
Appointed CFO
Director departure
Inv. presentation
Quarterly results
Consulting agrmnt
|
|
Alliqua BioMedical, Inc. (ADYX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/17/2019 |
8-K
| Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 11/14/2019 |
8-K
| Quarterly results |
| 10/02/2019 |
8-K
| Quarterly results |
| 08/14/2019 |
8-K
| Quarterly results|
Docs:
|
"Adynxx, Inc. Condensed Consolidated Statements of Operations Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 Operating expenses Research and development $ 1,895 $ 583 $ 3,226 $ 1,269 General and administrative 1,454 598 2,317 1,292 Grant reimbursements - - Total operating expenses, net 2,245 1,181 4,345 2,561 Loss from operations Interest expense, net Other income , net - 60 60 Loss from continuing operations Loss from discontinued operations - - Net loss $ $ $ $ Net loss per basic and diluted share: Loss from continuing operations $ $ $ $ Loss from discontinued operations - - Net loss per basic and diluted share $ $ $ $ Weighted-average number of common shares outstanding - basic and diluted 5,358,882 4,569,742 4,966,491 4,569,742 Adynxx, Inc. Condensed Co..." |
|
| 08/01/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Eq... |
| 07/22/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/26/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/17/2019 |
8-K
| Termination of a Material Definitive Agreement |
| 06/12/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 05/31/2019 |
8-K
| Changes in Registrant's Certifying Accountant, Departure of Directors or Certain Officers; Election of Directors; Appointment... |
| 05/09/2019 |
8-K
| Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-B...|
Docs:
|
"Certificate of Amendment to Certificate of Incorporation to Effect the Name Change",
"Certificate of Amendment to Certificate of Incorporation to Effect the Reverse Stock Split",
"Form of Common Stock Certificate",
"Loan and Security Agreement, and as amended from time to time, by and among Adynxx, Inc. and Oxford Finance LLC",
"Form of promissory note issued to Oxford Finance LLC",
"Form of warrant issued to Oxford Finance LLC",
"Offer Letter, by and between Rick Orr and Adynxx, Inc",
"Offer Letter, by and between Donald Manning, M.D., Ph.D., and Adynxx, Inc",
"Offer Letter, by and between Julien Mamet, Ph.D. and Adynxx, Inc",
"Adynxx, Inc. 2010 Equity Incentive Plan Adopted by the Board of Directors: December 8, 2010 Approved by the Stockholders: December 8, 2010 Termination Date: December 7, 2020 1. General. Eligible Stock Award Recipients. The persons eligible to receive Stock Awards are Employees, Directors and Consultants. Available Stock Awards. The Plan provides for the grant of the following Stock Awards: Incentive Stock Options, Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock Awards, and Restricted Stock Unit Awards. Purpose. The Company, by means of the Plan, seeks to secure and retain the services of the group of persons eligible to receive Stock Awards as set forth in Section 1, to provide incentives for such persons to exert maximum efforts for the success of the Company and a..." |
|
| 04/12/2019 |
8-K
| Quarterly results |
| 04/09/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/14/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/11/2019 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 01/03/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 12/13/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 11/28/2018 |
8-K
| Acquisition/merger/asset purchase announced |
| 11/13/2018 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
| 10/12/2018 |
8-K
| Quarterly results |
| 06/26/2018 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/11/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/07/2018 |
8-K
| Asset disposition |
| 04/30/2018 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 03/15/2018 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Amendment Agreement, by and among Alliqua BioMedical, Inc., AquaMed Technologies, Inc. and Perceptive Credit Holdings, LP",
"Bridge Loan Note, by and among Alliqua BioMedical, Inc., AquaMed Technologies, Inc. and Perceptive Credit Holdings, LP",
"General Release and Severance Agreement, by and between Alliqua BioMedical, Inc. and Brian Posner" |
|
| 02/09/2018 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 01/05/2018 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Asset Purchase Agreement, between Alliqua BioMedical, Inc. and Celularity Inc",
"Alliqua BioMedical, Inc. Announces Definitive Asset Purchase Agreement with Celularity, Inc. YARDLEY, PA., January 5, 2018 -- Alliqua BioMedical, Inc. , a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced a definitive agreement with Celularity, Inc. , under which Celularity will acquire all of the property, assets and rights relating to the Company’ s advanced biologic wound care business - including Biovance® amniotic membrane allograft and Interfyl® Human Connective Tissue Matrix - and the Company’ s UltraMist® Therapy System and other therapeutic ultrasound platform products for an aggregate cash consideration of $29.0 million. No debt or significant liabilities are being assumed by Celularity in the transaction. Alliqua BioMedical’ s ..." |
|
| 12/08/2017 |
8-K
| Resignation/termination of a director |
| 11/24/2017 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/09/2017 |
8-K
| Quarterly results|
Docs:
|
"Alliqua BioMedical, Inc. Reports Third Quarter of Fiscal Year 2017 Financial Results and Increases Fiscal Year 2017 Financial Outlook",
"Alliqua BioMedical, Inc. Engages Cowen to Assist in Evaluating Potential Strategic Alternatives YARDLEY, Pa., November 9, 2017 – Alliqua BioMedical, Inc. , a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced that it has engaged Cowen as its independent financial advisor to assist the Company in evaluating potential strategic alternatives. “The Board of Directors has decided to engage Cowen to comprehensively and systematically explore and review potential strategic alternatives. Importantly, this strategic process will not distract the organization from executing our strategic growth objectives and, in parallel, we will continue to evaluate all potential opportunities to improve the strength of our balance sheet. Our primary objective in ..." |
|
| 10/05/2017 |
8-K
| Quarterly results |
| 09/13/2017 |
8-K
| Quarterly results |
| 09/05/2017 |
8-K
| Quarterly results |
| 09/01/2017 |
8-K
| Quarterly results |
|
|
|